Search

To analyze the prognostic factors of transarterial chemoembolization (TACE) combined with antiviral therapy for hepatitis B virus (HBV)-associated hepatocellular carcinoma. This study included 130 patients with HBV-associated hepatocellular carcinoma admitted to the hospital from February 2018 to March 2020. All patients underwent TACE combined with antiviral therapy, and their survival status was recorded. The prognostic factors were analyzed. At the end of follow-up, 58 patients died and 72 patients survived, with a median survival time of 24 months. The 1-year and 2-year survival rates were 82.31% and 55.38%. Univariate analysis and multivariate Cox regression analysis found that the maximum tumor diameter, serum AFP, Child-Pugh grade, abdominal cavity metastasis, and portal vein tumor thrombus were risk factors for poor prognosis. The maximum tumor diameter, serum AFP, Child-Pugh grade, abdominal cavity metastasis, and portal vein tumor thrombus are factors affecting the prognosis of HBV-associated hepatocellular carcinoma treated with TACE combined with antiviral therapy. [ABSTRACT FROM AUTHOR]

Objective: To investigate the relationship between preoperative prognostic nutrition index (PNI) and prognosis of patients with lung squamous cell carcinoma and its predictive effect on postoperative recurrence and death. Methods: A total of 78 patients with lung squamous cell carcinoma who received treatment in our hospital from January 2017 to January 2019 were included. All patients had complete clinical data and pathological information, and they were reviewed and followed up in the outpatient department for 3 years. In addition to the lost cases, 76 patients were included, during the period, 43 patients recurred and 37 patients died. The 76 patients were divided into recurrence group (n=43) and non-recurrence group (n=33), death group (n=37) and survival group (n=39) according to the recurrence and death conditions. The independent risk factors affecting the recurrence and death of patients with lung squamous cell carcinoma were analyzed by univariate and multivariate Logistic regression. The receiver operating characteristic (ROC) curve was used to analyze the predictive efficacy and optimal cutoff value of PNI in the postoperative recurrence and death of patients with lung squamous cell carcinoma. Results: Univariate analysis showed that TNM stage, smoking years, diabetes, family history, PNI were the related factors affecting the postoperative recurrence of patients with lung squamous cell carcinoma (P<0.05). Gender, age, TNM stage, BMI, smoking history, smoking years and PNI were the related factors affecting the postoperative death of patients with lung squamous cell carcinoma (P<0.05). Multivariate Logistic regression model analysis showed that TNM stage III, long smoking years and family history were independent risk factors for postoperative recurrence of patients with lung squamous cell carcinoma, and PNI was protective factor (P<0.05). In addition, male, older age, TNM stage III, and longer smoking years were independent risk factors for postoperative death of patients with lung squamous cell carcinoma, and PNI was the protective factor (P<0.05). ROC results showed that the area under curve of PNI in predicting postoperative recurrence of patients with lung squamous cell carcinoma was 0.746 the sensitivity was 83.72%, the specificity was 63.64%, and the best cutoff value was less than or equal to 49.90. The area under curve of PNI in predicting postoperative survival of patients with lung squamous cell carcinoma was 0.761, the sensitivity was 86.49%, the specificity was 66.67%, and the best cutoff value was less than or equal to 50.41. Conclusion: PNI has high predictive efficacy for postoperative recurrence and survival of patients with lung squamous cell carcinoma, increasing PNI level has a positive effect on improving the prognosis of patients with lung squamous cell carcinoma. [ABSTRACT FROM AUTHOR]

Objective: To assess the clinicopathological benefit of bevacizumab (Bev.) in neoadjuvant chemotherapy (NAC) for rectal cancer patients and to investigate its influence on microvessel status in cancerous tissue. Methods: We retrospectively analyzed the data of 47 rectal cancer patients who received NAC with or without Bev. The objective response was evaluated using the maximum tumor diameter. Tumor regression grade was classified as a pathological response. Results: Thirty-one patients (66%) received NAC including Bev, as the Bev group; and the other 16 patients were treated without Bev, as the non-Bev group. The objective response rate was significantly higher in the Bev group than in the non-Bev group (64.5%vs.25.0%, p=0.015). The rate of pathological response was higher in the Bev group (41.9%) than in the non-Bev group (12.5 %, P=0.052), but difference was not statistically significant. The microvessel density (MVD) of the resected cancerous tissue was significantly lower in the Bev group than in the non-Bev group. Conclusions: The objective and pathological responses were better in patients treated with NAC plus Bev than in those who received NAC without Bev. Additionally, MVD in tumor tissues was inhibited in the patients treated with NAC plus Bev. [ABSTRACT FROM AUTHOR]